References
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine 2007; 176: 532–555
- Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systemic review and a meta analysis. Thorax 2004; 59: 574–580
- De Castro J, Hernández-Hernández A, Rodríguez MC, Sardina JL, Llanillo M, Sánchez-Yagüe J. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 2007; 18(1)43–51
- Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2008; 3(1)89–96
- Kuebler WM. Selectins revisited: The emerging role of platelets in inflammatory lung disease. The Journal of Clinical Investigation 2006; 116: 3106–3108
- Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagulation and Fibrinolysis 1998; 9(2)107–117
- Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets 2007; 18(5)319–328
- Fimognari FL, Scarlata S, Antonelli-Incalzi R. Why are people with ‘poor lung function' at increased atherothrombotic risk? A critical review with potential therapeutic indications. Current Vascular Pharmacology 2010; 8(4)573–586
- Davì G, Basili S, Vieri M, Cipollone F, Santarone S, Alessandri C, Gazzaniga P, Cordova C, Violi F. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. American Journal of Respiratory Critical and Care Medicine 1997; 156: 1794–1799
- Baudner S, Dati F. Standardisierung der Bestimmung von 14 Proteinen in Human-Serum auf der Basis des neuen IFCC/BCR/CAP Internationalen Referenzmetrials CRM 470. Journal of Laboratory Medicine 1996; 20: 145–152
- Radišić Biljak V, Rumora L, Čepelak I, Pancirov D, Popović-Grle S, Sorić J, Stjepanović G, Žanić-Grubišić T. Gamma-glutamyltransferase and C-reactive protein in stable chronic obstructive pulmonary disease. Collegium Antropologicum (in press).
- Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: A link between thrombosis and inflammation? Current Pharmaceutical Design 2011, Epub ahead of print.
- Onder I, Topcu S, Dökmetas HS, Türkay C, Seyfikli Z. Platelet aggregation size and volume in chronic obstructive pulmonary disease. Materia Medica Polona 1997; 29(1–4)11–13
- MacNee W. Oxidants and COPD. Current Drug Targets. Inflammation and Allergy 2005; 4(6)627–641
- Van Tiel E, Peeters PH, Smit HA, Nagelkerke NJ, Van Loon AJ, Grobbee DE, Bueno-de-Mesquita HB. Quitting smoking may restore hematological characteristics within five years. Annals of Epidemiology 2002; 12(6)378–388
- Aghaji M, Nnabuko R, Uzuegbunam C, Oyeka IC. The relationship of white blood cell and platelet counts to cigarette smoking in adult Nigerians. The Central African Journal of Medicine 1990; 36(11)273–278
- Mercelina-Roumans PE, Ubachs JM, van Werch JW. Platelet count and platelet indices at various stages of normal pregnancy in smoking and non-smoking women. European Journal of Clinical Chemistry and Clinical Biochemistry 1995; 33(5)267–269
- Gan WQ, Man SPF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127: 558–564